Shoko Matsui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoko Matsui has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Yamamoto
First Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan
4 shared publicationsKazunori Yamada
Affiliation Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan
3 shared publicationsMasamichi Komatsu
First Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan
3 shared publications- Minehiko Inomata
First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan
3 shared publications Mitsuhiro Kawano
Affiliation Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan
3 shared publicationsMotohisa Yamamoto
University of Tokyo, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 1 October 2023
- Published by Japan Society of Sarcoidosis and Other Granulomatous Disorders in The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
- Vol. 43 (1_2) , 93-97
新たなIgG4関連疾患診断基準―2020改訂IgG4関連疾患包括診断基準とThe 2019 ACR/EULAR classification criteria for IgG4-related disease
IgG4関連疾患(immunoglobulin G4-related disease: IgG4-RD)は,血清IgG4高値と病変部位へのIgG4陽性形質細胞浸潤を特徴とする疾患である.主な罹患臓器は,涙腺・唾液腺・膵臓などであるが,サルコイドーシスと同様に,全身の諸臓器に病変が生じる可能性がある.このIgG4関連疾患の包括診断基準が,2011年に本邦より発表されて以降,多くの症例や研究が報告されてきた.また2019年には米国・欧州のリウマチ学会から分類基準が発表され,2020年には包括診断基準の改訂も行われるなど,新たな動きもみられている.そのため本稿では,IgG4-RDの診断基準と分類基準について解説する.
- 1 October 2023
- Published by Japan Society of Sarcoidosis and Other Granulomatous Disorders in The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
- Vol. 43 (1_2) , 93-97
Open Access新たなIgG4関連疾患診断基準―2020改訂IgG4関連疾患包括診断基準とThe 2019 ACR/EULAR classification criteria for IgG4-related disease
IgG4関連疾患(immunoglobulin G4-related disease: IgG4-RD)は,血清IgG4高値と病変部位へのIgG4陽性形質細胞浸潤を特徴とする疾患である.主な罹患臓器は,涙腺・唾液腺・膵臓などであるが,サルコイドーシスと同様に,全身の諸臓器に病変が生じる可能性がある.このIgG4関連疾患の包括診断基準が,2011年に本邦より発表されて以降,多くの症例や研究が報告されてきた.また2019年には米国・欧州のリウマチ学会から分類基準が発表され,2020年には包括診断基準の改訂も行われるなど,新たな動きもみられている.そのため本稿では,IgG4-RDの診断基準と分類基準について解説する.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA2513
IgG4-related respiratory disease: a retrospective study of 115 patients
Background: IgG4-related disease comprises multiorgan diseases including pulmonary disorders. Though typical lesions are glandular lesions, various lesions are sometimes found in the respiratory system. Aims: This study aimed to clarify the clinical features of IgG4-related respiratory disease (IgG4-RRD). Method: The study group of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, conducted a multicenter retrospective study of IgG4-RRD in Japan and analyzed the collected data. Results: Data of 115 cases (mean 64.5 yrs. old, m:f 2.6:1) with intrathoracic lesions were collected among which 98% had one or more extrathoracic lesions when diagnosed as IgG4-RRD. The most prevalent symptoms at onset were submandibular gland swelling and cough (each 22.6%). Of the 115 patients, 76 (66%) had a past or present history of airway allergy among whom 18 had asthma, 27 had rhinitis, and the other 31 had both concomitantly.The most common affected organs concomitant with IgG4-RRD at diagnosis were sialadenitis (80% of 115), dacryoadenitis (49%) and pancreatitis (37%). In laboratory data, the mean serum levels of IgG and IgG4 were 2919 mg/dl and 1101 mg/dl, respectively. Hypocomplementemia was observed in 28%. Glucocorticoid (GC) therapy was administered to 94 cases (81.7%), among which over 90% responded well to GC therapy. The prevalence of concomitant malignant disease at diagnosis of IgG4-RRD was 2.6%, and that of malignancy during follow-up (mean 66.4 months) was 7.8%. Conclusions: Most IgG4-RRD patients had extrathoracic lesions and responded well to GC therapy. Concurrent malignant diseases at time of diagnosis and observed during follow-up of IgG4-RRD should be noted.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA2513
IgG4-related respiratory disease: a retrospective study of 115 patients
Background: IgG4-related disease comprises multiorgan diseases including pulmonary disorders. Though typical lesions are glandular lesions, various lesions are sometimes found in the respiratory system. Aims: This study aimed to clarify the clinical features of IgG4-related respiratory disease (IgG4-RRD). Method: The study group of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, conducted a multicenter retrospective study of IgG4-RRD in Japan and analyzed the collected data. Results: Data of 115 cases (mean 64.5 yrs. old, m:f 2.6:1) with intrathoracic lesions were collected among which 98% had one or more extrathoracic lesions when diagnosed as IgG4-RRD. The most prevalent symptoms at onset were submandibular gland swelling and cough (each 22.6%). Of the 115 patients, 76 (66%) had a past or present history of airway allergy among whom 18 had asthma, 27 had rhinitis, and the other 31 had both concomitantly.The most common affected organs concomitant with IgG4-RRD at diagnosis were sialadenitis (80% of 115), dacryoadenitis (49%) and pancreatitis (37%). In laboratory data, the mean serum levels of IgG and IgG4 were 2919 mg/dl and 1101 mg/dl, respectively. Hypocomplementemia was observed in 28%. Glucocorticoid (GC) therapy was administered to 94 cases (81.7%), among which over 90% responded well to GC therapy. The prevalence of concomitant malignant disease at diagnosis of IgG4-RRD was 2.6%, and that of malignancy during follow-up (mean 66.4 months) was 7.8%. Conclusions: Most IgG4-RRD patients had extrathoracic lesions and responded well to GC therapy. Concurrent malignant diseases at time of diagnosis and observed during follow-up of IgG4-RRD should be noted.
- Open Access
- 26 April 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (17) , 1618-1623
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice
Objective: Studies have suggested the potential efficacy of immune checkpoint inhibitors (ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was conducted to evaluate the efficacy of systemic ICI therapy and chemoradiation followed by durvalumab therapy for pulmonary sarcomatoid carcinoma.Methods: We analyzed the data of patients with pulmonary sarcomatoid carcinoma who received systemic ICI therapy or chemoradiation followed by durvalumab therapy between 2016 and 2022.Results: In this study, data of a total of 22 patients who received systemic ICI therapy and four patients who received chemoradiation followed by durvalumab therapy were analyzed. In the patients who received systemic ICI therapy, the median progression‐free survival after initiation of therapy was 9.6 months, and the overall survival did not reach the median. The 1‐year progression‐free survival rate and overall survival rate were estimated to be 45.5% and 50.1%, respectively. Although the log‐rank test revealed no significant association between the tumor expression level of programmed death ligand‐1 (tumor proportion score evaluated using 22C3 antibody: ≥50% vs. <50%) and the survival duration, the majority of patients showing long‐term survival showed a tumor proportion score of ≥50%. Of four patients treated with chemoradiation followed by durvalumab therapy, two patients showed an overall survival of ≥30 months, whereas the remaining two patients died within 12 months.Conclusion: The progression‐free survival of patients who received systemic ICI therapy was 9.6 months, suggesting that ICI therapy might be effective in patients with pulmonary sarcomatoid carcinoma.
- 26 April 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (17) , 1618-1623
Open AccessEfficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice
Objective: Studies have suggested the potential efficacy of immune checkpoint inhibitors (ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was conducted to evaluate the efficacy of systemic ICI therapy and chemoradiation followed by durvalumab therapy for pulmonary sarcomatoid carcinoma.Methods: We analyzed the data of patients with pulmonary sarcomatoid carcinoma who received systemic ICI therapy or chemoradiation followed by durvalumab therapy between 2016 and 2022.Results: In this study, data of a total of 22 patients who received systemic ICI therapy and four patients who received chemoradiation followed by durvalumab therapy were analyzed. In the patients who received systemic ICI therapy, the median progression‐free survival after initiation of therapy was 9.6 months, and the overall survival did not reach the median. The 1‐year progression‐free survival rate and overall survival rate were estimated to be 45.5% and 50.1%, respectively. Although the log‐rank test revealed no significant association between the tumor expression level of programmed death ligand‐1 (tumor proportion score evaluated using 22C3 antibody: ≥50% vs. <50%) and the survival duration, the majority of patients showing long‐term survival showed a tumor proportion score of ≥50%. Of four patients treated with chemoradiation followed by durvalumab therapy, two patients showed an overall survival of ≥30 months, whereas the remaining two patients died within 12 months.Conclusion: The progression‐free survival of patients who received systemic ICI therapy was 9.6 months, suggesting that ICI therapy might be effective in patients with pulmonary sarcomatoid carcinoma.
- Open Access
- 20 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Purpose: We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods: We retrieved the patient data from the medical charts. Patients who were diagnosed as having EGFR-mutant NSCLC and treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) between 2007 and 2020 at our institution were included in the analysis. Results: A total of 130 patients were included in the analysis. A log-rank test identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential osimertinib therapy for patients with the T790M mutation acquired after primary EGFR-TKI therapy as being significantly associated with a better overall survival. Analysis using a Cox proportional hazards model identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib as being independently associated with a prolonged overall survival. Conclusion: Our analysis suggested that EGFR mutation status, an Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib were associated with overall survival in patients with EGFR-mutant NSCLC in clinical practice settings.
- 20 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
Open AccessImpact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Purpose: We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods: We retrieved the patient data from the medical charts. Patients who were diagnosed as having EGFR-mutant NSCLC and treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) between 2007 and 2020 at our institution were included in the analysis. Results: A total of 130 patients were included in the analysis. A log-rank test identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential osimertinib therapy for patients with the T790M mutation acquired after primary EGFR-TKI therapy as being significantly associated with a better overall survival. Analysis using a Cox proportional hazards model identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib as being independently associated with a prolonged overall survival. Conclusion: Our analysis suggested that EGFR mutation status, an Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib were associated with overall survival in patients with EGFR-mutant NSCLC in clinical practice settings.
- Open Access
- 4 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0247173
The pronounced lung lesions developing in LATY136F knock-in mice mimic human IgG4-related lung disease
Rationale: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a novel clinical disease entity characterized by an elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. Pathological changes are most frequently seen in the pancreas, lacrimal glands, and salivary glands, but pathological changes in the lung also exist. Linker for activation of T cell (LAT)Y136F knock-in mice show Th2-dominant immunoreactions with elevated serum IgG1 levels, corresponding to human IgG4. We have reported that LATY136F knock-in mice display several characteristic features of IgG4-RD and concluded that they constitute an appropriate model of human IgG4-RD in salivary glands, pancreas, and kidney lesions. Objectives: The aim of this study is to evaluate whether lung lesions in LATY136F knock-in mice can be a model of IgG4-related lung disease. Methods: Lung tissue samples from LATY136F knock-in mice (LAT) and wild-type mice (WT) were immunostained for IgG1 and obtained for pathological evaluation, and cell fractions and cytokine levels in broncho-alveolar lavage fluid (BALF) were analyzed. Results: In the LAT group, IgG1-positive inflammatory cells increased starting at 4 weeks of age and peaked at 10 weeks of age. The total cell count and percentage of lymphocytes increased significantly in BALF in the LAT group compared to the WT group. In BALF, Th2-dominant cytokines and transforming growth factor-β were also increased. In the LAT group, marked inflammation around broncho-vascular bundles peaked at 10 weeks of age. After 10 weeks, fibrosis around broncho-vascular bundles and bronchiectasis were observed in LATY136F knock-in mice but not WT mice. Conclusions: LATY136F knock-in mice constitute an appropriate model of lung lesions in IgG4-RD.
- 4 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0247173
Open AccessThe pronounced lung lesions developing in LATY136F knock-in mice mimic human IgG4-related lung disease
Rationale: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a novel clinical disease entity characterized by an elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. Pathological changes are most frequently seen in the pancreas, lacrimal glands, and salivary glands, but pathological changes in the lung also exist. Linker for activation of T cell (LAT)Y136F knock-in mice show Th2-dominant immunoreactions with elevated serum IgG1 levels, corresponding to human IgG4. We have reported that LATY136F knock-in mice display several characteristic features of IgG4-RD and concluded that they constitute an appropriate model of human IgG4-RD in salivary glands, pancreas, and kidney lesions. Objectives: The aim of this study is to evaluate whether lung lesions in LATY136F knock-in mice can be a model of IgG4-related lung disease. Methods: Lung tissue samples from LATY136F knock-in mice (LAT) and wild-type mice (WT) were immunostained for IgG1 and obtained for pathological evaluation, and cell fractions and cytokine levels in broncho-alveolar lavage fluid (BALF) were analyzed. Results: In the LAT group, IgG1-positive inflammatory cells increased starting at 4 weeks of age and peaked at 10 weeks of age. The total cell count and percentage of lymphocytes increased significantly in BALF in the LAT group compared to the WT group. In BALF, Th2-dominant cytokines and transforming growth factor-β were also increased. In the LAT group, marked inflammation around broncho-vascular bundles peaked at 10 weeks of age. After 10 weeks, fibrosis around broncho-vascular bundles and bronchiectasis were observed in LATY136F knock-in mice but not WT mice. Conclusions: LATY136F knock-in mice constitute an appropriate model of lung lesions in IgG4-RD.
- Open Access
- 25 November 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (12) , 1006
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Background: Among patients with non-small cell lung cancer (NSCLC), we compared the progression-free survival (PFS) and proportion of acquisition of T790M mutation of the epidermal growth receptor gene (EGFR) after first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patient groups with and without tumor expression of programmed death ligand-1 (PD-L1). Methods: Data of patients with EGFR-mutant NSCLC were retrospectively analyzed. Tumor PD-L1 expression was evaluated by immunohistochemistry using the 22C3 antibody. T790M gene mutation was evaluated by Cobas EGFR assay using tissues or humoral specimens. Results: Data of 47 patients with EGFR-mutant NSCLC were analyzed. The median (95% confidence interval) PFS in the PD-L1-negative and -positive patient groups were 12.9 (9.7–15.4) months and 9.0 (5.1–12.3) months, respectively (p = 0.029). T790M gene mutation was analyzed in 27 patients. The proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI was higher in the PD-L1-negative patient group than in the PD-L1-positive patient group (8/11 patients (72.7%) vs. 4/16 patients (25.0%); p = 0.022). Conclusions: Patients with negative tumor PD-L1 expression showed longer PFS and a higher proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI.
- 25 November 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (12) , 1006
Open AccessAssociation of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Background: Among patients with non-small cell lung cancer (NSCLC), we compared the progression-free survival (PFS) and proportion of acquisition of T790M mutation of the epidermal growth receptor gene (EGFR) after first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patient groups with and without tumor expression of programmed death ligand-1 (PD-L1). Methods: Data of patients with EGFR-mutant NSCLC were retrospectively analyzed. Tumor PD-L1 expression was evaluated by immunohistochemistry using the 22C3 antibody. T790M gene mutation was evaluated by Cobas EGFR assay using tissues or humoral specimens. Results: Data of 47 patients with EGFR-mutant NSCLC were analyzed. The median (95% confidence interval) PFS in the PD-L1-negative and -positive patient groups were 12.9 (9.7–15.4) months and 9.0 (5.1–12.3) months, respectively (p = 0.029). T790M gene mutation was analyzed in 27 patients. The proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI was higher in the PD-L1-negative patient group than in the PD-L1-positive patient group (8/11 patients (72.7%) vs. 4/16 patients (25.0%); p = 0.022). Conclusions: Patients with negative tumor PD-L1 expression showed longer PFS and a higher proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI.
- 2 January 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (1) , 235-240
Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis
Objectives: Immunoglobulin G4-related disease (IgG4-RD) is a systemic, multiorgan disease of unknown etiology. We aimed to classify IgG4-RD by a combination pattern of affected organs and identify the clinical features, including the comorbidities of each subgroup. Methods: Patients diagnosed with IgG4-RD between April 1996 and June 2018 were enrolled from three institutes. Hierarchical cluster analysis was performed using six frequently affected organs (lacrimal gland and/or orbit, salivary gland, lung, pancreas, kidney, and retroperitone and/or aorta). Clinical features, such as comorbidities and outcomes, were compared between clusters. Results: In total, 108 patients enrolled in this cohort could be stratified into five distinct subgroups: group 1, lung dominant group; group 2, retroperitoneal fibrosis and/or aortitis dominant group; group 3, salivary glands limited group; group 4, Mikulicz’s disease dominant group; and group 5, autoimmune pancreatitis with systemic involvement group. There were significant between-group differences in sex (male dominant in group 1, 2, and 5), history of asthma and allergies on the respiratory tract (most frequent in group 5), and malignancy (most frequent in group 5). Conclusion: IgG4-RD can be classified into subgroups according to the pattern of affected organs. Group 5 may have frequent complications with allergies and malignancies.
- 2 January 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (1) , 235-240
Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis
Objectives: Immunoglobulin G4-related disease (IgG4-RD) is a systemic, multiorgan disease of unknown etiology. We aimed to classify IgG4-RD by a combination pattern of affected organs and identify the clinical features, including the comorbidities of each subgroup. Methods: Patients diagnosed with IgG4-RD between April 1996 and June 2018 were enrolled from three institutes. Hierarchical cluster analysis was performed using six frequently affected organs (lacrimal gland and/or orbit, salivary gland, lung, pancreas, kidney, and retroperitone and/or aorta). Clinical features, such as comorbidities and outcomes, were compared between clusters. Results: In total, 108 patients enrolled in this cohort could be stratified into five distinct subgroups: group 1, lung dominant group; group 2, retroperitoneal fibrosis and/or aortitis dominant group; group 3, salivary glands limited group; group 4, Mikulicz’s disease dominant group; and group 5, autoimmune pancreatitis with systemic involvement group. There were significant between-group differences in sex (male dominant in group 1, 2, and 5), history of asthma and allergies on the respiratory tract (most frequent in group 5), and malignancy (most frequent in group 5). Conclusion: IgG4-RD can be classified into subgroups according to the pattern of affected organs. Group 5 may have frequent complications with allergies and malignancies.
- 2 January 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (1) , 241-248
Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney disease
Objectives: This study investigated the clinical features of IgG4-RKD patients with hypocomplementemia compared with those without it, so as to clarify the factors related to hypocomplementemia. Methods: In this single-center retrospective study, we analyzed the clinical features of 25 patients with IgG4-RKD according to the presence/absence of hypocomplementemia. Additionally, we validated the results of a single-center study in a separate large multicenter cohort of 328 patients with IgG4-RD, and searched for factors related to hypocomplementemia. Results: Serum IgG levels (P < 0.001), non-IgG4 IgG levels, calculated as the total IgG minus IgG4 (P < 0.001), serum IgG1 levels (P = 0.017), and the number of involved organs (P = 0.018) were significantly higher in the hypocomplementemia group. At relapse of renal lesions in four patients, all had serum IgG4 re-elevation, with the three with hypocomplementemia presenting worsening of hypocomplementemia and re-elevation of non-IgG4 IgG levels. In a validation cohort of 328 patients with IgG4-RD, multivariate logistic regression analysis indicated elevation of non-IgG4 IgG levels to be an independent factor related to hypocomplementemia in the patients with IgG4-RKD. Conclusions: The present study suggests that hypocomplementemia is associated with elevation of IgG subclasses other than IgG4 including IgG1 in IgG4-RKD.
- 2 January 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (1) , 241-248
Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney disease
Objectives: This study investigated the clinical features of IgG4-RKD patients with hypocomplementemia compared with those without it, so as to clarify the factors related to hypocomplementemia. Methods: In this single-center retrospective study, we analyzed the clinical features of 25 patients with IgG4-RKD according to the presence/absence of hypocomplementemia. Additionally, we validated the results of a single-center study in a separate large multicenter cohort of 328 patients with IgG4-RD, and searched for factors related to hypocomplementemia. Results: Serum IgG levels (P < 0.001), non-IgG4 IgG levels, calculated as the total IgG minus IgG4 (P < 0.001), serum IgG1 levels (P = 0.017), and the number of involved organs (P = 0.018) were significantly higher in the hypocomplementemia group. At relapse of renal lesions in four patients, all had serum IgG4 re-elevation, with the three with hypocomplementemia presenting worsening of hypocomplementemia and re-elevation of non-IgG4 IgG levels. In a validation cohort of 328 patients with IgG4-RD, multivariate logistic regression analysis indicated elevation of non-IgG4 IgG levels to be an independent factor related to hypocomplementemia in the patients with IgG4-RKD. Conclusions: The present study suggests that hypocomplementemia is associated with elevation of IgG subclasses other than IgG4 including IgG1 in IgG4-RKD.
- 11 July 2019
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 30 (3) , 551-557
Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD
[Background] IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and tissue infiltration by IgG4-positive plasma cells. The pathogenesis of this disease is not clear. Transcriptome analysis was performed to identify genes over- and under-expressed in patients with IgG4-RD. [Method] DNA microarray analysis was performed using RNA from peripheral blood mononuclear cells of two patients with IgG4-RD and four healthy individuals. Genes showing a greater than 3-fold change in expression in IgG4-RD patients following steroid therapy were identified. Four genes related to innate immunity such as transcobalamin I (TCN1), secretory leukocyte peptidase inhibitor (SLPI), bactericidal/permeability-increasing protein (BPI) and lactotransferrin (LTF) were assessed by real-time PCR in 15 IgG4-RD patients and 13 healthy individuals. [Result] DNA microarray analysis identified 30 genes showing a greater than 3-fold change in expression in IgG4-RD patients following steroid therapy. Real-time RT-PCR showed that the levels of mRNAs encoding TCNI and SLPI, except for BPI and LTF, were significantly lower in patients with IgG4-RD than in healthy people. The levels of all four mRNAs in patients with IgG4-RD were significantly increased after steroid treatment. [Conclusion] These results indicate that reduction in expression of innate immunity-related genes may participate in the pathogenesis of IgG4-RD that steroid treatment may rectify impaired innate immunity as well as acquired immunity.
- 11 July 2019
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 30 (3) , 551-557
Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD
[Background] IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and tissue infiltration by IgG4-positive plasma cells. The pathogenesis of this disease is not clear. Transcriptome analysis was performed to identify genes over- and under-expressed in patients with IgG4-RD. [Method] DNA microarray analysis was performed using RNA from peripheral blood mononuclear cells of two patients with IgG4-RD and four healthy individuals. Genes showing a greater than 3-fold change in expression in IgG4-RD patients following steroid therapy were identified. Four genes related to innate immunity such as transcobalamin I (TCN1), secretory leukocyte peptidase inhibitor (SLPI), bactericidal/permeability-increasing protein (BPI) and lactotransferrin (LTF) were assessed by real-time PCR in 15 IgG4-RD patients and 13 healthy individuals. [Result] DNA microarray analysis identified 30 genes showing a greater than 3-fold change in expression in IgG4-RD patients following steroid therapy. Real-time RT-PCR showed that the levels of mRNAs encoding TCNI and SLPI, except for BPI and LTF, were significantly lower in patients with IgG4-RD than in healthy people. The levels of all four mRNAs in patients with IgG4-RD were significantly increased after steroid treatment. [Conclusion] These results indicate that reduction in expression of innate immunity-related genes may participate in the pathogenesis of IgG4-RD that steroid treatment may rectify impaired innate immunity as well as acquired immunity.